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O B J E C T I V E S The purpose of this study was to test the lipid depletion hypothesis and to establish
the time course of change in carotid plaque morphology and composition during lipid therapy using
high-resolution magnetic resonance imaging (MRI).
B A C KG ROUND Lipid therapy is thought to improve plaque stability and reduce cardiovascular
events by targeting the plaque rupture risk features such as large lipid core, thin ﬁbrous cap, and high
level of inﬂammatory inﬁltrates. However, the plaque stabilizing process during lipid therapy has not
been clearly demonstrated in humans and in vivo.
METHOD S Subjects with coronary or carotid artery disease, apolipoprotein B120 mg/dl, and lipid
treatment history 1 year, were randomly assigned to atorvastatin monotherapy or to atorvastatin-
based combination therapies with appropriate placebos for 3 years. All subjects underwent high-
resolution, multicontrast bilateral carotid MRI scans at baseline and annually for 3 years. All images were
analyzed for quantiﬁcation of wall area and plaque composition blinded to therapy, laboratory results,
and clinical course.
R E S U L T S After 3 years of lipid therapy, the 33 subjects with measurable lipid-rich necrotic core
(LRNC) at baseline had a signiﬁcant reduction in plaque lipid content: LRNC volume decreased from 60.4 
59.5 mm3 to 37.4  69.5 mm3 (p  0.001) and %LRNC (LRNC area/wall area in the lipid-rich regions) from
14.2  7.0% to 7.4  8.2% (p  0.001). The time course showed that %LRNC decreased by 3.2 (p  0.001)
in the ﬁrst year, by 3.0 (p 0.005) in the second year, and by 0.91 (p 0.2) in the third year. Changes in LRNC
volume followed the same pattern. Percent wall volume (100  wall/outer wall, a ratio of volumes) in the
lipid-rich regions signiﬁcantly decreased from 52.3 8.5% to 48.6 9.7% (p 0.002). Slices containing LRNC
had signiﬁcantly more percent wall volume reduction than those without (4.7% vs. 1.4%, p  0.02).
CONC L U S I O N S Intensive lipid therapy signiﬁcantly depletes carotid plaque lipid. Statistically
signiﬁcant plaque lipid depletion is observed after 1 year of treatment and continues in the second
year, and precedes plaque regression. (Using Magnetic Resonance Imaging to Evaluate Carotid
Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications [The CPC Study];
NCT00715273). (J Am Coll Cardiol Img 2011;4:977–86) © 2011 by the American College of
Cardiology Foundation
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he hypothesis of lipid depletion for plaque
and clinical stability has been established on
the basis of observations from animal studies
(1–4), correlation of histological features in
uman coronary plaque with unstable clinical epi-
odes (5–9), and angiographic regression and clin-
cal event reduction with lipid-lowering therapy
10,11). In a case-control study of patients ran-
omly allocated to 3 months of pravastatin treat-
ent or placebo before carotid endarterectomy,
risby et al. (12) provided histological evidence of
See page 987
the efficacy of therapy on plaque lipid content.
However, in vivo verification of the lipid depletion
hypothesis and establishment of the time course of
plaque regression has not been possible until re-
cently (13,14).
Development of high-resolution mag-
netic resonance imaging (MRI) tech-
niques in recent years has made direct
assessment of plaque tissue composition
possible. Numerous studies have shown
that MRI exhibits high contrast for
internal plaque features, and that com-
bined information from multiple con-
trast weightings is critical for distin-
guishing all plaque components (15–20).
With confirmation by histological stud-
ies, high-resolution multicontrast MRI
can accurately assess plaque tissue con-
tents (21–23).
We designed and conducted a ran-
domized, double blind, and partial
placebo-controlled study entitled The CPC
Study (Carotid Plaque Composition by MRI
During Lipid-Lowering) to test 2 hypotheses: 1)
intensive lipid therapy will deplete plaque lipid
content; and 2) low-density lipoprotein choles-
terol (LDL-C) lowering plus high-density lipo-
protein cholesterol (HDL-C) raising, compared
to LDL-C lowering alone, or similar HDL-C
raising with further LDL-C lowering will lead to
more plaque depletion. The primary endpoint is
the carotid plaque lipid content as measured by
University of Washington, Seattle, Washington; §The Mountain-Whis
Heart Center, Yakima, Washington; and ¶St. Luke’s Idaho Cardiology A
by a National Institutes of Health grant (R01 HL63895) from the Natio
Inc. The study medications are provided by Pfizer Inc., Abbott Labora
reported they have no relationships relevant to the contents of this paper
a
tein
reManuscript received December 15, 2010; revised manuscript received May 2MRI. The secondary endpoints include plaque
burden and other plaque tissue contents. This
report describes the study results of the first
hypothesis.
M E T H O D S
Study subjects. Details of the study design have
been previously published (24). Briefly, participants
were recruited from the University of Washington
Medical Center Cardiac Catheterization Labora-
tory, the Yakima Heart Center Cardiac Catheter-
ization Laboratory, and the St. Luke’s Idaho Car-
diology Associates in Boise. Subjects who met the
following criteria were approached for the study:
1) angiographically confirmed coronary artery dis-
ease (defined as having at least 1 50% stenosis or 3
30% coronary lesions, or being post–myocardial
infarction, post–percutaneous coronary interven-
tion, or post–coronary artery bypass graft surgery)
or carotid disease (defined as having a 15%
stenosis by ultrasonography); 2) apolipoprotein
(Apo) B 120 mg/dl; 3) duration of lipid therapy
before enrollment 1 year; and 4) no contraindi-
cation for gadolinium-based contrast-enhanced ca-
rotid MRI. The study procedures and consent
forms were approved by the University of Wash-
ington institutional review board.
Among the 123 subjects enrolled in the study,
mean age was 55 years, mean body mass index was
30 kg/m2, 73% were male, 43% had a family history
of premature cardiovascular disease, 37% had a
previous myocardial infarction, 80% had clinically
established coronary artery disease, 52% were hy-
pertensive, 12% had diabetes mellitus, 23% were
current smokers, and 47% met the criteria for
metabolic syndrome. The mean baseline total cho-
lesterol was 238 mg/dl, triglycerides were 202
mg/dl, LDL-C was 163 mg/dl, HDL-C was 41
mg/dl, HDL2 was 7.4 mg/dl, ApoB was 131 mg/dl,
ApoA1 was 129 mg/dl, lipoprotein(a) was 69
nmol/l, fasting glucose level was 103 mg/dl, insulin
level was 25 U/dl, and median high-sensitivity
C-reactive protein was 1.8 mg/l. The mean ( SD)
lipid treatment history before enrollment was 7  4
onths.
Light Statistics, Seattle, Washington; Yakima
ciates, Boise, Idaho. This research is supported
Heart, Lung, and Blood Institute, and by Pfizer
es, and Daiichi Sankyo, Inc. The authors have
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CIMT carotid intima-medi
thickness
ER extended release
HDL-C high-density
lipoprotein cholesterol
LDL-C low-density lipopro
cholesterol
LRNC lipid-rich necrotic co
MRImagnetic resonance
imaging6, 2011, accepted June 8, 2011.
b
G
e
c
1
r
c
r
M
c
r
w
s
f
s
fl
w
c
c
e
m
m
t
a
w
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 9 , 2 0 1 1
S E P T E M B E R 2 0 1 1 : 9 7 7 – 8 6
Zhao et al.
MRI of Plaque Lipid Depletion
979Of the 123 subjects, 33 with acceptable image
quality, measurable lipid-rich necrotic core
(LRNC) on baseline carotid MRI and LRNC
measurements at year 3 were selected to test the
hypothesis that intensive lipid therapy will deplete
plaque lipid content.
Lipid treatments and clinical follow-up. All subjects
were randomly assigned to 1 of 3 treatment groups:
1) single therapy: atorvastatin (10 to 80 mg/day)
alone, placebos for extended release (ER) niacin and
colesevelam; 2) double therapy: atorvastatin plus
ER-niacin (2 g/day), and placebo for colesevelam;
3) triple therapy: atorvastatin, ER-niacin plus co-
lesevelam (3.8 g/day). The treatment target for
LDL-C was 80 mg/dl for the single-therapy and
double-therapy groups and 60 mg/dl for the
triple-therapy group. The HDL-C target for the 2
niacin-treated groups was to increase 10 mg/dl from
baseline.
All subjects were followed up monthly for the
first 6 months and then bimonthly for the remain-
ing 30 months of the 36-month protocol. A total of
21 visits per subject was conducted for this study.
At these visits, subjects underwent questioning
about side effects and symptomatic state as well as a
targeted cardiovascular examination. Any adverse
events, both cardiovascular and noncardiovascular,
were collected. At approximately 50% of the visits,
blood samples were drawn (50 ml). In all treat-
ment arms, dietary counseling was targeted at
weight reduction with goals based on the level of
obesity, with additional emphasis on the use of
monounsaturated fats in a fat-limited (25% to 30%)
diet.
As published previously (25), after 1 year of the
study therapy, on average, ApoB was reduced by
40%, 45%, and 51% among single-, double-, and
triple-therapy groups, respectively; and LDL-C was
lowered by 47%, 47%, and 57%, respectively; trig-
lycerides decreased by 25%, 33%, and 42%, respec-
tively; and HDL-C was increased by 12%, 25%,
and 29%, respectively.
Carotid MRI scans. High-resolution, multicontrast
ilateral carotid MRI scans were performed on a
E 1.5-T Signa whole body scanner using a 5.6
cho speed platform (Waukesha, Wisconsin). The
arotid MR scans were obtained at baseline, and at
, 2, and 3 years. All follow-up MRI scans were
epeated using the same imaging protocol and
arefully matched for scan coverage using the ca-
otid bifurcation as internal landmark.
Subjects were placed in the supine position in the
RI scanner with the neck extended to bring thearotid arteries into a more superficial location
elative to the skin. A custom designed head holder
as used to minimize subject movement. Two
eparate phased-array carotid coils (26) were used
or simultaneous bilateral scan. As described in the
tudy methodology (24), 2-dimensional time-of-
ight, proton density, and T2-weighted and T1-
eighted images were acquired. The longitudinal
overage of this set of images (10 to 12 slices) was
entered at the carotid bifurcation and covered the
ntire most likely diseased region. Then 20 ml (0.1
mol/kg) of gadolinium contrast material was ad-
inistrated intravenously though a power injector;
he T1 scan was repeated 5 to 7 min after contrast
dministration. The total scan time for each subject
as 40 to 50 min.
MRI analysis for quantiﬁcation of plaque size and tissue
composition. Images were analyzed by experienced
reviewers in the Vascular Imaging Laboratory at the
University of Washington. A peer-review process
was conducted to reach consensus on each of the
reviews. The image analyses were blinded to ther-
apy, laboratory results, and clinical course. One
experienced reviewer (B.A.P.), blinded to treatment
and time points, matched the axial images from
different time points according to their distance
from the bifurcation of the carotid artery (carotid
bifurcation was always used as the landmark for
orientation and coverage). The results were peer
reviewed by other experienced reviewers (H.U. and
B.C.) who were also blinded to therapy and time
points. All reviewers separately interpreted each
image, and the reviewers conferred to reach a
consensus opinion.
Total vessel area was quantified by placing con-
tours around the outer wall boundaries of the
carotid artery using CASCADE (27), a custom-
designed image analysis tool. Similarly, lumen area
was quantified by placing contours around the
lumen boundary, and wall area was calculated by
subtracting the lumen area from the total vessel
area. Lumen, wall, and total vessel volumes were
derived by adding the areas across slices and mul-
tiplying by the sum by the slice thickness (2 mm).
Percent wall volume (PWV) was calculated using
the following formula: (wall volume/total vessel
volume)  100%. The PWV provides a measure of
plaque burden that adjusts for variation in artery
size, and is similar to percent atheroma volume
described in the intravascular ultrasound literature.
Carotid plaque tissue composition (LRNC, fi-
brous tissue, loose matrix, and calcification) was
identified and quantified using previously published
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980MRI criteria (19,23). Specifically, LRNC was iden-
tified using multicontrast weightings plus post-
contrast T1-weighted images. LRNC usually appears
isointense to hyperintense on the time-of-flight and
pre-contrast T1-weighted images and has varied
signal intensity on protein density weighted and
T2-weighted images, has no or slight contrast
enhancement compared with the surrounding tissue
on post-contrast T1-weighted images. Plaque com-
ponent volumes were calculated as described above,
and the proportional volume of each component
was calculated using the formula: (component vol-
ume/wall volume)  100%.
The plaque LRNC, as the primary end point of
the study, was assessed in 2 different ways: 1) total
LRNC volume; and 2) percent LRNC (%LRNC)
relative to the lipid-containing slices only. As illus-
trated in Figure 1, the total LRNC volume was
measured by multiplying the slice thickness by the
sum of the LRNC areas (circled in yellow) on the 8
consecutive images from common carotid through
bifurcation to the internal carotid arteries. The
Figure 1. Example of Carotid Artery in Multicontrast MRI
Magnetic resonance imaging (MRI) example of 8 consecutive image
internal carotid arteries (ICA) from 5 contrast weightings: time of ﬂi
T1-weighted (T1W), and post-contrast T1W. The lumen in red and o
outlined. Plaque tissue components within the arterial wall are iden
purple and lipid content in yellow). For example, lipid content in y
and hypointense on PDW and T2W images, and has no contrast en
T1W images. Total lipid-rich necrotic core (LRNC) volume is calculat
circled in yellow color on the 8 consecutive images. Percent LRNC
the lipid-containing slices, from slice #2 to #7.%LRNC was calculated based only on the slices
containing a LRNC (slices #2 to #7 in this exam-
ple).
Statistical analysis. In all analyses, the artery was
sed as the unit of observation. That is, in a given
nalysis, slice values of the outcome within a given
ubjects were pooled (as described previously) to
roduce 1 value per subject. Data from 1 carotid
rtery (the index artery with more lesion) per
ubject were used in the analysis. Descriptive sta-
istics are presented as mean  SD. Changes
etween carotid scans were annualized because of
he variation in time between visits across subjects.
hanges over time were compared to zero using the
ilcoxon signed-rank test or the 1-sample t test.
he t test was used for carotid wall measurement
ata, which were reasonably similar to the normal
istribution. Normality of outcomes was assessed by
-Q plots. The Wilcoxon signed-rank test was
arried out for comparisons involving plaque tissue
omponents, which sometimes had non-normal
istributions. Change in %LRNC and PWV were
the common carotid artery (CCA) through bifurcation to the
(TOF), proton density weighted (PDW), T2-weighted (T2W),
r wall boundary in blue of the carotid artery are identiﬁed and
d using an established algorithm and quantiﬁed (loose matrix in
w appears isointense on the TOF and pre-contrast T1W images
cement compared with the surrounding tissue on post-contrast
y multiplying the slice thickness (2 mm) by the sum of the areas
RNC) is the proportion of the wall occupied by the LRNC only ins of
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981correlated with changes with lipid variables using
Spearman correlation. Calculations were carried out
in R, version 2.9.0 (28) All p values 0.05 were
considered statistically significant.
R E S U L T S
Change in plaque lipid content. Among the 123
ubjects enrolled in this study, 33 subjects with
easureable LRNC at baseline who completed
-year follow-up scans and had acceptable image
uality were included in this comparison. Six sub-
ects were excluded because of poor image quality.
nother 81 subjects had no measurable LRNC at
aseline and were excluded from the analysis. Finally,
subjects with LRNC at baseline did not complete
-year follow-up scans and were excluded, too.
After 3 years of intensive lipid therapy, LRNC
olume significantly decreased from a mean  SD
f 60.4  59.5 mm3 to 37.4  69.5 mm3 (p 
.001) and %LRNC from 14.2  7.0% to 7.4 
.2% (p  0.001), as summarized in Figure 2. An
xample of a carotid plaque with reduction in
RNC size is shown in Figure 3A.
There were 5 subjects who had new measurable
RNC at some point during the 3 years. Only 1 of
hese 5 subjects had measurable LRNC at the
-year scan. Among the 75 study subjects with all 4
%
 L
RN
C
Baseline Year 1 Yea
p<0.001*
p
* Compared to Baseline
§ Year 2 compared to year 10
5
10
15
Figure 2. Carotid Plaque Lipid Depletion and Time Course Duri
After 3 years of intensive lipid therapy, lipid-rich necrotic core volu
to 37.4 mm3. Percent LRNC (%LRNC) (pink circles) also signiﬁcantly
course over 3 years showed that %LRNC for pooled slices containin
year, signiﬁcantly decreased by 3.0% in the second year, and decre
statistically signiﬁcant). Bars around the estimates are standard error bannual measurements, the overall number of sub-
ects with measurable LRNC was significantly re-
uced over the 3 years: 44% at baseline versus 33%
t 3 years (p  0.03, McNemar test).
Plaque lipid depletion time course. The year-by-year
laque lipid depletion time course is also illustrated
n Figure 2. The mean LRNC volume significantly
ecreased by 12 mm3 (p  0.007) in the first year,
y 13 mm3 (p  0.004) in the second year, and
ncreased nonsignificantly by 0.4 mm3 (p  0.3) in
he third year. Similarly, mean %LRNC among
ipid-containing slices significantly decreased by 3.2
p  0.001) in the first year, by 3.0 (p  0.005) in
the second year, and reduced nonsignificantly by 0.9
(p  0.2) in the third year. Figure 3B demonstrates
n MRI example of plaque lipid depletion and
egression in plaque volume over 3 years.
Changes in other plaque tissue components. Figure 4
shows plaque fibrous tissue, calcium, and loose
matrix changes among lipid-containing slices over 3
years. Compared to baseline, the volume of fibrous
tissue significantly decreased (571 mm3 vs. 547
mm3, p  0.007), but percent of plaque composed
of fibrous tissue significantly increased (83.4% vs.
90.1%, p  0.001) during the 3 years. The mean
volume of fibrous tissue decreased slightly in the
first year and significantly in the second year. Mean
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982percent fibrous tissue increased significantly during
each of the first 2 years. Both volume and percent of
fibrous tissue did not change significantly in the
third year. Calcium and loose matrix, both in
volume and percent composition, remained at a
similar level over the 3 years.
Carotid arterial wall burden change and its time
course. Three-year and annual changes in total
all volume, PWV, and lumen volume were
ssessed to describe and test carotid atheroscle-
otic burden change in subjects with measurable
RNC at baseline. As shown in Table 1, after 3
ears of intensive lipid therapy, total wall volume
nd PWV decreased significantly, but there was
o statistically significant change in lumen vol-
me. Time course showed no statistically signif-
cant change in wall volume or PWV in the first
Figure 3. MRI Examples of Plaque Lipid Depletion and Time Co
(A) An example of signiﬁcant lipid content reduction (yellow arrow
carotid artery. Overall, 11% of study subjects had completed plaque
example of the plaque lipid depletion time course. Regression in lip
1-year, and 2-year MRI scans. Regression in plaque volume seemed
years 1 to 3. CE  contrast enhanced; T1W  T1-weighted.ear, but significant changes during the second sear, as wall volume decreased by 42 mm3 (p 
.001 for 2-year volume compared to baseline;
 0.01 compared to year 1) and PWV was
educed by 2.1% (p  0.001 for 2-year compared
o baseline, p  0.01 compared to year 1). The
hanges in the third year were minimal.
Difference in wall volume change between slices with
and without LRNC. As also shown in Table 1, the
lices with LRNC showed a significant mean de-
rease in total wall volume and PWV over 3 years.
he reduction in wall burden measurements in
lices without LRNC showed the same direction as
n slices with LRNC but was smaller and not
tatistically significant. Furthermore, both for wall
olume and PWV, the 2 measures of wall burden,
he differences in reduction between the slices with
nd without LRNC at baseline were statistically
nd plaque regression at 3 years compared to baseline in the left
id depletion over 3 years. (B) Magnetic resonance imaging (MRI)
ich necrotic core (LRNC) size was notable between the baseline,
ollow plaque lipid depletion and was most pronounced fromurse
s) a
lip
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to fignificant.
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983Relation between plaque and lipid changes. Spear-
an correlation analysis showed no statistically
ignificant association between change in %LRNC
nd PWV as assessed by MRI and change in lipid
ariables over 3 years among the 33 subjects with
easurable LRNC at baseline in this report. Ob-
erved Spearman correlations ranged in magnitude
rom 0.00 to 0.31. The lipid variables include
hanges in total cholesterol, very low density lipo-
rotein cholesterol, intermediate-density lipopro-
ein cholesterol, LDL-C, HDL-C, HDL-C2,
DL-C3, ApoB, ApoA1, and triglycerides.
D I S C U S S I O N
The most widely accepted hypothesis is that lipid-
lowering therapy targets the plaque rupture risk
features such as large lipid core, thin fibrous cap,
and high level of inflammatory infiltrates and activ-
ity; therefore, the plaque stability is improved and
cardiovascular events are reduced. The evidence
from diet-induced atherosclerosis animal models
%
 C
A
Baseline Year 
1.0
1.5
2.0
%
 F
T
Baseline Year 1 Year 2 Year 3
FT
-
V 
(m
m3
)
80
85
90
95 600
580
560
540
520
500
FT-V
% FT
Figure 4. Carotid Plaque Tissue Composition Change Over 3-Ye
Changes in plaque ﬁbrous tissue (FT), calcium (CA), and loose matr
cles), over 3 years. CA  calcium; FT  ﬁbrous tissue; LM  loose
percent of ﬁbrous tissue increased. These changes were signiﬁcant
signiﬁcantly over 3 years. Bars around the estimates are standard e
Table 1. Carotid Wall Measurements Change Over 3 Years and
Comparison: Baseline vs. 3 Yrs
n Baseline 3 Yrs p Value‡
Wall volume, mm3 33 641 200 597 198 0.001
Percent wall volume, % 33 46.5 7.1 44.3 7.2 0.006
Lumen volume, mm3 33 750 249 764 258 0.110
Values are mean SD for the comparison of baseline versus 3 years and mean
times between the visits for different subjects. The calculation of changes was
versus 3 years. †The smaller sample size (n  31) was the results of 2 patients
0.001 when compared to null hypothesis of zero change. p  0.01 when compare(1–4) showed that lowering cholesterol can de-
crease foam cells and cholesterol ester content at 6
months, diminish cholesterol crystals and necrosis
at 12 months, and reduce plaque size at 24 to 48
months. The CPC study, 1 of the first studies
testing the lipid depletion hypothesis in humans
and in vivo, demonstrated that intensive lipid ther-
apy significantly depletes plaque lipid content over 3
years. We found a 6.8% absolute reduction in
lipid-containing segment (14.2% at baseline vs.
7.4% at 3 years) with intensive lipid therapy and
11% lower frequency of subjects with measurable
LRNC (44% at baseline vs. 33% at 3 years). These
reductions were statistically significant.
Histological studies of human coronary plaques
have demonstrated an association between features
such as the presence of a large lipid core, thin
fibrous cap, and high concentration of inflamma-
tory infiltrates with prior unstable clinical events
(5–9). In the carotid artery, MRI has provided an
essential tool for identifying potential high-risk
%
 L
M
Baseline Year 1 Year 2 Year 3
LM
-V
 (m
m3
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% LM
Year 2 Year 3
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m3
)
12
10
8
6
4
-V
CA
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M), both volume (V) (green squares) and composition (pink cir-
ix. Compared to baseline, volume of ﬁbrous tissue decreased, but
ach of the ﬁrst 2 years. Calcium and loose matrix did not change
bars.
erential Changes Between Slices With and Without LRNC
Annual Changes*
Comparison: Chang
LRNC () vs
n 1st Yr 2nd Yr 3rd Yr n LRNC () L
30 16 62 42 57§ 3 34 31 45 55¶ 
30 0.6 2.9 2.1 3.2§ 0.2 2.5 31 4.7 7.1¶ 
30 2 50 18 52 5 42 31 12 41
or each annual change during the 3 years. *Changes between the scans were annu
ed to patients with all 4 annual visits. Thus, the sample size is smaller than for th
having both lipid-rich necrotic core (LRNC) positive () and LRNC negative () s1
CA
% 
ar L
ix (L
matr
at eDiff
e Over 3 Yrs Slices
. LRNC ()†
RNC () p Value‡
11 32 0.004
1.4 3.2 0.020
7 40 0.300
SE f alized because of different
limit e comparison of baseline
not lices. ‡Paired t test. §p d to year 1. ¶p  0.001 when compared to zero change.
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984plaque features associated with more rapid progres-
sion and future ischemic events. In a recent pro-
spective natural history study of carotid atheroscle-
rosis, Underhill et al. (29) showed that carotid
plaques with larger LRNC at baseline were associ-
ated with a significantly higher risk of plaque
surface disruption on 3-year follow-up carotid
MRI. Furthermore, in a prospective study of sub-
jects with initially asymptomatic 50% to 79% ca-
rotid stenosis, Takaya et al. (30) found that plaques
with larger LRNC were associated with a higher
risk of cerebrovascular events during a mean
follow-up of 3 years (hazard ratio for every 10%
increase in LRNC size: 1.6, p 0.004). The plaque
lipid depletion demonstrated in this study suggest a
potential mechanism by which aggressive lipid ther-
apy results in plaque stabilization and a lower risk
for future ischemic events, and provides compelling
evidence to justify larger prospective clinical trials to
this hypothesis.
This study also demonstrated that significant
plaque lipid depletion can be achieved after 1 year
of intensive treatment, continues with a similar rate
of change during the second year, and begins to
plateau during the third year. The time course for
plaque lipid depletion demonstrated in this study
provides a vascular biological explanation for the onset
and persistence of clinical benefit seen in the
placebo-controlled lipid-lowering trials (10). The
cardiovascular event reduction in these trials began
at 1 to 2 years after initiation of lipid-lowering
therapy, which corresponds with the timing of
significant plaque lipid depletion and increase in
percent fibrous tissue at 1 and 2 years observed in
this study. The temporal relationship between the
plaque biological changes and clinical event reduc-
tion during lipid therapy will be further examined in
our on-going studies.
In addition to reduction in lipid core volume,
regression in overall plaque burden was observed,
primarily after 2 to 3 years of intensive lipid therapy,
consistent with the observations from animal stud-
ies (1–4), and consistent with plaque burden regres-
sion seen in other lipid-lowering studies in humans
(13,31,32). We believe that the regression observed
in plaque burden was primarily induced by lipid
depletion because:1) substantial and statistically sig-
nificant carotid wall burden reduction only occurred
in the slices containing a LRNC; and 2) the time
course of wall burden reduction seemed to follow
plaque lipid depletion, with the largest changes
occurred during the second year. aThe temporal relationship between plaque lipid
and plaque burden regression, and the observed
regression only at sites with a LRNC may also help
to explain the inconsistent results seen in studies
using carotid intima-media thickness (CIMT) as a
marker for regression during LDL-C–lowering
therapy. In the METEOR (Effect of Rosuvastatin
on Progression of Carotid Intima-Media Thickness
in Low-Risk Individuals With Subclinical Athero-
sclerosis) study (33), where relatively statin-naïve
subjects with thick CIMTs were recruited (baseline
CIMT of 1.16 mm, and hence more likely to have
lipid-rich plaques), statistically significant differ-
ences between treatment groups were observed
(0.014 mm/year). In contrast, the ENHANCE
(Simvastatin With or Without Ezetimibe in Famil-
ial Hypercholesterolemia) study (34), where subjects
had been treated for an extended period of time, and
had a relative normal CIMT at baseline (0.68 mm and
more likely to have lipid-poor plaques) showed a very
small difference (0.005 mm per 2 years) between
groups. Once atherosclerotic plaque lipid has been
depleted and regression has achieved with therapy,
further treatment is certainly necessary to keep plaque
stable without significant progression, but maybe un-
likely to induce further regression.
Although there are no statistically significant cor-
relations between the plaque changes, in both
%LRNC and PWV, and the lipid variables, this does
not indicate there is no differential treatment effect
among the 3 different lipid therapies, because only 33
subjects were included in the current correlation anal-
ysis. The differential treatment effect will be investi-
gated fully when the CPC study is closed, and it will
be further examined in the carotid MRI substudy in
the AIM-HIGH (Atherothrombosis Intervention in
Metabolic syndrome with low HDL/high triglycer-
ides: Impact on Global Health outcomes) trial in
approximately 200 subjects (35).
The effects of the 3 treatment therapies may have
introduced some heterogeneity into the responses.
This increase in variability, if it occurred, would tend
to decrease power to detect changes and identify
correlates of change. Thus, statements of statistical
significance in this paper may be conservative. It is
unlikely that statistically significant differences noted
here are artifacts. Statistically significant differences
and associations observed in this study—with a sample
size of 40 subjects—can be attributed to several
spects of the study, including: 1) a relatively
reatment-naive population; 2) potent lipid modifica-
ion on both LDL-C and HDL-C, and; 3) highly
ccurate assessment of plaque change by MRI.
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In conclusion, intensive lipid therapy significantly
depletes carotid atherosclerotic plaque lipid in
humans. Statistically significant plaque lipid de-
pletion is observed after 1 year of treatment and
continues in the second year. Regression in over-
all plaque burden was observed primarily at loca-
tions with a LRNC, and its time course follows
plaque lipid depletion. These findings suggest aMacrophages and atherosclerotic
1
1
1
1
1
1
1
1
MR imaging for idsociated with intensive lipid therapy. Further-
more, these results highlight the importance of
selection of subjects with a LRNC in future trials
examining the effect of therapy on plaque regres-
sion.
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